(NASDAQ: ZYME) Zymeworks's forecast annual revenue growth rate of 25.27% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.57%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.16%.
Zymeworks's revenue in 2024 is $76,012,000.On average, 6 Wall Street analysts forecast ZYME's revenue for 2024 to be $5,875,016,186, with the lowest ZYME revenue forecast at $1,764,205,550, and the highest ZYME revenue forecast at $10,662,858,344. On average, 5 Wall Street analysts forecast ZYME's revenue for 2025 to be $8,737,051,566, with the lowest ZYME revenue forecast at $2,117,046,660, and the highest ZYME revenue forecast at $19,205,141,617.
In 2026, ZYME is forecast to generate $10,270,993,007 in revenue, with the lowest revenue forecast at $2,469,887,770 and the highest revenue forecast at $16,032,394,356.